Action CUV CLINUVEL PHARMACEUTICALS LIMITED
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Clinuvel Pharmaceuticals Limited

Actions

CUV

AU000000CUV3

Marché Fermé - Australian S.E.
Autres places de cotation
 08:10:53 18/04/2024 		Varia. 5j. Varia. 1 janv.
15,29 AUD +0,92 % Graphique intraday de Clinuvel Pharmaceuticals Limited +0,07 % -4,44 %
14/03 Clinuvel Pharmaceuticals lance un programme de rachat d'actions MT
14/03 CLINUVEL PHARMACEUTICALS LIMITED : Morgans Financial désormais positif sur le dossier ZM

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Photomedicine Pioneer CLINUVEL Unveils Clinical, Cosmetic Ambitions to German Investors
Clinuvel Pharmaceuticals Launches Share Buyback Program
Clinuvel Pharmaceuticals Limited announces an Equity Buyback for 1,500,000 shares, representing 2.99% of its issued share capital.
Clinuvel Pharmaceuticals Limited authorizes a Buyback Plan.
Biotech-Unternehmen CLINUVEL launcht Photomedizin-Stiftung bei Event von Lady Gaga
Malibu shines a light on CLINUVEL’s pioneering work in photomedicine
Clinuvel Reports Positive Results in SCENESSE Study
Clinuvel Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2023
Clinuvel Pharmaceuticals Limited Announces Change to Registered Office
Clinuvel Doses First Patient in Phase 3 Trial of Vitiligo Treatment
Clinuvel Pharmaceuticals Limited Announces Board Changes
Clinuvel Pharmaceuticals Teams Up With Vitiligo Experts to Assess Scenesse
Clinuvel Pharmaceuticals Limited Announces Dividend for the Full Year Ended June 30, 2023, Payable on September 20, 2023
Clinuvel Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended June 30, 2023
Clinuvel Pharmaceuticals Secures Supply Contract for Porphyria Medication with the US Department of Veterans Affairs
Clinuvel Pharmaceuticals Secures Patents for Melanocortins for Treatment of Central Nervous System Disorders
Clinuvel Pharmaceuticals Treats First Patient in Phase Two Stroke Trial
Clinuvel Pharmaceuticals Limited Announces Technical Note - CUV803 Study and AIS
Clinuvel Pharmaceuticals Limited Announces First Stroke Patient Treated with PRENUMBRA Instant
Clinuvel Pharmaceuticals Limited Present DNA Repair Data At American Academy of Dermatology Meeting
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action CUV
  4. Actualités Clinuvel Pharmaceuticals Limited
  5. Autres langues